Affiliation: Pfizer Global Research and Development
- Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?Ilise Lombardo
Pfizer Inc, New York, NY 10017, USA
J Clin Psychopharmacol 32:470-8. 2012..Rating reliability warrants further investigation to improve clinical trial methodology in psychiatry...
- Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidoneW Gordon Frankle
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, USA
J Psychopharmacol 25:734-43. 2011..The finding of a relationship between 5-HT(1A) binding and the degree of improvement in negative symptoms provides further support for the role of the 5-HT(1A) receptor in the pathophysiology and treatment of this symptom domain...
- The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trialKuan Gandelman
Clinical Pharmacology, Pfizer Inc, New York, NY 10017, USA
J Clin Psychiatry 70:58-62. 2009....
- Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorderLewis Warrington
Pfizer Inc, New York, New York 10017, USA
CNS Drugs 21:835-49. 2007..The favourable tolerability of ziprasidone has been confirmed in long-term extension studies and its use was not associated with weight gain or dyslipidaemia. Ziprasidone-related movement disorders occurred infrequently...